CellOrigin Biotech collaborates with Qilu Pharma to develop off-the-shelf CAR-iMAC cell therapy

CellOrigin Biotech (Hangzhou) Co., Ltd. announced it has made a global strategic collaboration agreement with Qilu Pharma to develop, manufacture and commercialize proprietary "off-the-shelf" induced pluripotent stem cell- (iPSC) derived Chimeric Antigen Receptor Macrophages (CAR-iMAC) for cancer immunotherapy. The collaboration will take advantages of technologies and expertise from both parties, as well as integrate capabilities of R&D, manufacturing and marketing to develop CAR-iMAC clinical products aiming for solid tumours. "Innovation and offering the best products that benefit patients are the core values that CellOrigin Biotech and Qilu Pharma both appreciate," said Dr. Jin Zhang, the co-founder of CellOrigin Biotech and a Principal Investigator of Zhejiang University, one of the top universities in China. "This is what brings us together." "We are very excited to collaborate with Qilu Pharma because of its prestige in the field of Chinese pharmaceutical industry, as well as its tremendous track records on drug development," said Dr. Jiansong Tong, the chief executive officer at CellOrigin Biotech. "Meanwhile, we will continue to seek other potential collaborators to jointly develop our innovative anti-tumour CAR-iMac cell products." "CellOrigin Biotech is a startup company established by a group of outstanding scientists who have tremendous experiences both in R&D research and cGMP manufacture. It focused on developing innovative technologies in cell therapy and building valuable pipeline of products. It is an ideal strategic partner for novel cell therapy, and it is our pleasure to collaborate with such a great biotech company," said Qilu Pharma. CellOrigin Biotech (Hangzhou) Co., Ltd. is dedicated to the development of genetically engineered pluripotent stem cell- (iPSC) derived immune cell therapies (such as macrophages, NK cells), with its own proprietary intellectual property. Qilu Pharma is a leading vertically integrated pharmaceutical companies in China focused on discovering, developing, manufacturing and commercializing innovative medicines.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!